Selective MC2R Antagonist for ACTH-Driven Cortisol Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions associated with excess adrenocorticotropic hormone (ACTH), such as Cushing's disease, congenital adrenal hyperplasia, and ectopic ACTH syndrome, are limited by side effects and inefficiencies, particularly in reducing cortisol and androgen levels, and there is a need for a more selective and effective pharmacological approach.
Innovation Solution
A selective non-peptide small molecule melanocortin 2 receptor (MC2R) antagonist, Compound 1, is administered to selectively inhibit ACTH activity, thereby reducing cortisol and androgen production in the adrenal glands without affecting mineralocorticoid production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for excess ACTH conditions are used, then cortisol and androgen levels are reduced, but side effects increase and treatment efficiency is limited
Solution Approach 1:
The patent employs parameter changes by developing Compound 1 with optimized chemical structure parameters (molecular weight, lipophilicity, binding affinity) to achieve selective MC2R antagonism. The compound's specific structural parameters enable it to bind selectively to MC2R with high affinity while minimizing interactions with other receptors, thereby improving treatment efficiency and reducing side effects compared to existing therapies
Solution Approach 2:
The invention applies local quality by designing a compound with specific functional groups and molecular characteristics tailored for MC2R selectivity. The compound's structure incorporates specific pharmacophore elements that confer selective binding to MC2R, allowing the treatment to act locally and specifically on ACTH-mediated cortisol and androgen production without broadly affecting other hormonal pathways, thus reducing systemic side effects
2Quantity of substance
If non-selective ACTH inhibitors are used, then cortisol levels are reduced, but mineralocorticoid production is also affected
Solution Approach 1:
The patent utilizes parameter changes by optimizing Compound 1's binding parameters for MC2R specificity. The compound's molecular parameters are tuned to recognize and bind specifically to the MC2R binding pocket, which is responsible for ACTH-mediated cortisol production, while not interfering with other receptor subtypes involved in mineralocorticoid regulation. This selective parameter optimization ensures cortisol reduction without compromising mineralocorticoid production
Solution Approach 2:
The invention applies segmentation by targeting a specific receptor subtype (MC2R) within the broader melanocortin receptor family. By segmenting the therapeutic approach to act only on MC2R rather than all melanocortin receptors, the compound achieves selective inhibition of ACTH's effect on cortisol production while leaving other hormonal pathways, including mineralocorticoid production, unaffected
Data Source
AI summary
Provided herein are methods and compositions for the treatment of diseases of ACTH excess, such as Cushing's disease, ectopic ACTH syndrome, and congenital adrenal hyperplasia.